Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
We’re the world’s leading provider of drug, device, company, clinical trial and market intelligence in the competitive pharma and medtech markets.
We provide unrivalled and daily-updated global insight, drawn from extensive authoritative data sets and enriched by human validation.
Our premium quality data is drawn from 42,000 companies, 248,000 clinical trials in 175 countries and 65,000 drugs for 1,400 diseases.
Our bespoke clinical, commercial and market access solutions are designed to help you make smarter decisions that bring a better return on investment.
Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.
We’re the trusted partner of more than 3,000 companies including the top 50 pharma firms and top 10 contract research organizations.
Our customer services team will support you every step of the way so that our insight, intelligence and bespoke solutions match your needs.
From single reports and data downloads to enterprise subscriptions to custom consultancy, we can base our precise solutions round your exact needs.
Get coverage of the latest pharmaceutical business developments, and historical metrics on financing, licensing, partnership, and acquisition.
Our trusted Pharma Intelligence brands
Datamonitor Healthcare
By Ljlal Syed, Mark Lansdell and David Abramson 19 Sep 2017
This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic
Topic Deal trends
Datamonitor Healthcare
By Colin White, Robert Jeng & Jolene Lau 19 Sep 2017
This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well
Topic immuno-oncology
Medtech Insight
By Jenny Blair 19 Sep 2017
End-stage renal disease (ESRD) affects 600,000 Americans, striking over 120,000 people a year, and most of these patients require renal replacement therapy.
Pink Sheet
By Emily Hayes 18 Sep 2017
An 'imperfect biomarker' – that's how a New England Journal of Medicine editorial describes the eosinophil count used in METREX and METREO studies.
Topic Clinical trials
Medtech Insight
By Amanda Maxwell 18 Sep 2017
If there is a delay in appointing EU notified bodies under the new Medical Device and IVD Regulations.
Datamonitor Healthcare
By Dustin Phan 18 Sep 2017
Recently, Informa Pharma Intelligence conduced an insightful webinar regarding the current market landscape and outlook for immuno-oncology.
Topic immuno-oncology
Topic Medtech weekly roundup
Trialtrove, Pharmaprojects
By Laura Runkel 18 Sep 2017
As clinical and diagnostic parameters evolve over time, Trialtrove strives to reflect them in our patient segments and disease coverage.
Topic Clinical trials blog
Medtrack
By Steven Muntner 16 Sep 2017
Royalty payments are an essential component of most pharmaceutical deals. Along with upfront payments and milestones, companies are rewarded for surpassing certain developmental hurdles.
Topic Deal trends Medtech
Pink Sheet
By Ian Schofield 16 Sep 2017
Massimo Scaccabarozzi, president of Italy’s Farmindustria and Janssen Italy’s MD, warns that the EMA could lose almost all of its current staff.
Topic Brexit
Scrip
By Joseph Haas 16 Sep 2017
CEO Crowley points to the need to focus on a pair of Fabry candidates, including the pending NDA for migalastat, and notes that other companies have reached Phase III in EB.
Topic Clinical trials
Scrip
By Kevin Grogan 16 Sep 2017
Roger Dansey, head of Merck's clinical development in oncology, tells Scrip that the Keynote clinical program for the blockbuster PD-1 inhibitor continues to hit endpoints.
Topic Clinical trials
In Vivo
By John Hodgson 16 Sep 2017
As a new generation of biosimilars challenge some of pharma’s biggest-selling products, this In Vivo analysis looks at how the originator blockbuster might fare in the face of competition.
Topic Biosimilars
Pink Sheet
By Cathy Kelly 16 Sep 2017
Biopharma manufacturers, payers and other stakeholders strongly support changing an Obama-era policy for reimbursing biosimilars.
Topic Biosimilars
Pink Sheet
21 Sep 2017
Pink Sheet
21 Sep 2017
Scrip
20 Sep 2017
Pink Sheet
20 Sep 2017
In Vivo
20 Sep 2017
Scrip
20 Sep 2017
Medtech Insight
20 Sep 2017
Scrip
20 Sep 2017
Pink Sheet
20 Sep 2017
Pink Sheet
20 Sep 2017
Medtech Insight
20 Sep 2017
Pink Sheet
20 Sep 2017
Pink Sheet
20 Sep 2017
Pink Sheet
19 Sep 2017
Scrip
19 Sep 2017
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Key benefits:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
Key benefits:
21 Sep 2017 , 16:00 BST
Webinar
29 Nov 2017
Awards
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Report store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
